ApreMilast Good Manufacturer supply High Quality 608141-41-9
- Molecular Formula:C22H24N2O7S
- Molecular Weight:460.508
- Boiling Point:741.342 °C at 760 mmHg
- PKA:14.01±0.20(Predicted)
- Flash Point:402.149 °C
- PSA：127.46000
- Density:1.382 g/cm3
- LogP:3.52590
ApreMilast (608141-41-9) Usage
Apremilast is the first and only oral phosphodiesterase IV (PDE- 4) inhibitor and anti-tumor necrosis factor alpha (TNFa) agent launched in the USA by Celgene for the treatment of active psoriatic arthritis (PsA). Apremilast was also approved for the treatment of moderate to severe plaque psoriasis in the USA. Later, this drug was also approved in the European Union (EU) for both indications. Although multiple approaches to the synthesis of apremilast have been described, the most likely process scale approach involves the construction of the challenging stereogenic benzylic carbon center by catalytic asymmetric hydrogenation.
How to get the best price on ApreMilast?
Zibo Hangyu Biotechnology Development Co., Ltd is a quality supplier and manufacturer of ApreMilast . You can buy high quality, low price ApreMilast 608141-41-9 here.
Zibo Hangyu Biotechnology Development Co., Ltd. is a comprehensive chemical enterprise focusing on fine chemical products and pharmaceutical intermediates, integrating research and development, production and sales. The company is equipped with advanced equipment quality inspection and research center. At the same time, the company has excellent talents with rich experience in process development and quality control. To provide customers with total solutions from raw material processing to chemical synthesis systems. The company has established a standardized and perfect quality standard system to provide stable and high quality production and service.
Milestones
- 2012yearThe company was founded, began to engage in the production and supply of chemical raw materials
- 2014yearExpand the scale of production, pharmaceutical raw materials production workshop was established
- 2016yearCooperated with domestic and foreign chemical platforms to promote self-produced and high-end pharmaceutical intermediates
- 2019yearIn recent years to participate in the international pharmaceutical raw materials exhibitions
- 2023yearBusiness continues to expand, Production and Sales teams continue to grow
- 2026yearPlans to set up foreign branches
